Frequently Asked Questions
The market is segmented based on , By Type (Adenocarcinoma, Lymphoma, Gastrointestinal Stromal Tumor, Carcinoid Tumor, Others), Stages (Stage I, Stage II, Stage III, Stage IV, Others), Diagnosis (Endoscopy, Biopsy, Imaging Tests, Exploratory Surgery, Others), Treatment (Surgery, Radiation Therapy, Chemotherapy, Targeted Therapy, Palliative Care, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029.
.
The Global Gastric Cancer Market size was valued at USD 4.00 USD Billion in 2021.
The Global Gastric Cancer Market is projected to grow at a CAGR of 16% during the forecast period of 2022 to 2029.
The major players operating in the market include Mylan N.V., Teva Pharmaceutical Industries , Sanofi, Pfizer , GSK plc, Novartis AG, Bayer AG, Eli Lilly and Company, Merck & Co., Johnson & Johnson Private Limited, Cipla , Abbott, AbbVie , Sun Pharmaceutical Industries , Aurobindo Pharma, Lupin, Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals , Eisai Co., Provell Pharmaceuticals, Piramal Critical Care.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
